Intermediate uveitis

disease

On this page

Also known as intermediate uveitis (disease)IUpars planitis

Summary

Intermediate uveitis (MONDO:0006806) is a disease and 11 clinical trials. Top therapeutic interventions include dexamethasone and triamcinolone acetonide. A subtype of uveitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

Prevalence: Unknown (Worldwide)
Phenotypes (HPO): 18
Clinical trials: 11

Clinical features

Signs & symptoms

Clinical features (HPO)

18 HPO clinical features (Orphanet curated; top 18 by frequency):

HPO ID	Term	Frequency
HP:0040049	Macular edema	Frequent (30-79%)
HP:0000501	Glaucoma	Occasional (5-29%)
HP:0000518	Cataract	Occasional (5-29%)
HP:0000585	Band keratopathy	Occasional (5-29%)
HP:0002633	Vasculitis	Occasional (5-29%)
HP:0007663	Reduced visual acuity	Occasional (5-29%)
HP:0011484	Posterior synechiae of the anterior chamber	Occasional (5-29%)
HP:0011505	Cystoid macular edema	Occasional (5-29%)
HP:0012122	Anterior uveitis	Occasional (5-29%)
HP:0030652	Vitreous haze	Occasional (5-29%)
HP:0030661	Vitreous snowballs	Occasional (5-29%)
HP:0100014	Epiretinal membrane	Occasional (5-29%)
HP:0100653	Optic neuritis	Occasional (5-29%)
HP:0100832	Vitreous floaters	Occasional (5-29%)
HP:0003765	Psoriasiform dermatitis	Very rare (<1-4%)
HP:0031035	Chronic infection	Very rare (<1-4%)
HP:0200056	Macular scar	Very rare (<1-4%)
HP:0001970	Tubulointerstitial nephritis	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	intermediate uveitis
Mondo ID	MONDO:0006806
EFO	EFO:1000986
MeSH	D015867
Orphanet	279914
DOID	DOID:12732
ICD-11	892860325
NCIT	C35110
SNOMED CT	314429009
UMLS	C0042166
MedGen	22596
GARD	0021065
MedDRA	10022557
Is cancer (heuristic)	no

Also known as: intermediate uveitis · intermediate uveitis (disease) · IU · pars planitis

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of uveitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › uveal disorder › uveitis › intermediate uveitis

Subtypes (2): pars planitis, hyalitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 6 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Fluocinolone Acetonide	Phase 3 (in late-stage trials)
Interferon Beta	Phase 3 (in late-stage trials)
Methotrexate	Phase 3 (in late-stage trials)
Mycophenolic Acid	Phase 3 (in late-stage trials)
Prednisone	Phase 3 (in late-stage trials)
Voclosporin	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Dexamethasone, Piclidenoson, Sirolimus.

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE2/PHASE3	2
PHASE1/PHASE2	2
PHASE4	1
PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02764697	PHASE4	COMPLETED	Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients
NCT00333814	PHASE2/PHASE3	COMPLETED	A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis
NCT02746991	PHASE3	COMPLETED	Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis
NCT05337332	PHASE2/PHASE3	UNKNOWN	Results of Suprachoroidal Steroids Injections in Two Chorioretinal Diseases
NCT01280669	PHASE2	WITHDRAWN	Intravitreal Sirolimus as Therapeutic Approach to Uveitis
NCT01717170	PHASE1/PHASE2	UNKNOWN	Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study
NCT01789320	PHASE1/PHASE2	COMPLETED	Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis
NCT00908466	PHASE1	COMPLETED	Sirolimus as Therapeutic Approach to Uveitis
NCT00570830	Not specified	COMPLETED	Retisert and Cataract Surgery in Patients With Severe Uveitis
NCT02879084	Not specified	COMPLETED	Variations in Retinal Nerve Fiber Layer Thickness During Uncomplicated Anterior and Intermediate Uveitis
NCT04126850	Not specified	UNKNOWN	Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis Disease

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DEXAMETHASONE	4	1
TRIAMCINOLONE ACETONIDE	4	1

Drugs: Dexamethasone, Triamcinolone Acetonide